Patents by Inventor Lakhmir S. Chawla
Lakhmir S. Chawla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230226141Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: ApplicationFiled: January 23, 2023Publication date: July 20, 2023Inventor: Lakhmir S. CHAWLA
-
Patent number: 11629383Abstract: Methods and kits for diagnosing and/or treating a lower respiratory infection in a subject include obtaining a biological sample from the subject; detecting RNA expression levels of one or more biomarkers in the biological sample and comparing the expression levels of the one or more three biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of the one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.Type: GrantFiled: October 27, 2020Date of Patent: April 18, 2023Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventors: Timothy A. Mccaffrey, Lakhmir S. Chawla
-
Patent number: 11559559Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: GrantFiled: July 20, 2021Date of Patent: January 24, 2023Assignee: The George Washington University, A Congressionally Chartered Not-For-Profit CorporationInventor: Lakhmir S. Chawla
-
Publication number: 20220298574Abstract: The invention relates to methods and kits for diagnosing and/or treating appendicitis in a subject, comprising performing one or more assays configured to detect one or more biomarkers on a body fluid sample obtained from the subject to provide one or more assay result(s) and correlating the assay result(s) to the occurrence or nonoccurrence of appendicitis in the subject or likelihood of the future outcome to the subject.Type: ApplicationFiled: June 5, 2022Publication date: September 22, 2022Inventors: Lakhmir S. CHAWLA, Timothy A. McCAFFREY, Paul McPHERSON, James Patrick KAMPF
-
Patent number: 11371096Abstract: The invention relates to methods and kits for diagnosing and/or treating appendicitis in a subject, comprising performing one or more assays configured to detect one or more biomarkers on a body fluid sample obtained from the subject to provide one or more assay result(s) and correlating the assay result(s) to the occurrence or nonoccurrence of appendicitis in the subject or likelihood of the future outcome to the subject.Type: GrantFiled: October 22, 2015Date of Patent: June 28, 2022Assignee: The George Washington University A Congressionally Chartered Not-For-Profit CorporationInventors: Lakhmir S. Chawla, Timothy A. McCaffrey
-
Publication number: 20220090199Abstract: The invention relates to methods and kits for diagnosing and/or treating appendicitis in a subject, comprising obtaining a biological sample rom said subject; detecting RNA expression levels of at least three or more biomarkers in the biological sample and comparing the expression levels of said at least three or more biomarkers to a control sample wherein an increase or decrease in the level of expression of said at least three or more biomarkers as compared to the control sample is indicative of appendicitis.Type: ApplicationFiled: June 9, 2021Publication date: March 24, 2022Inventors: Lakhmir S. CHAWLA, Timothy A. McCAFFREY
-
Publication number: 20220047669Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: ApplicationFiled: July 20, 2021Publication date: February 17, 2022Inventor: Lakhmir S. CHAWLA
-
Patent number: 11096983Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 6.5 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: GrantFiled: April 12, 2019Date of Patent: August 24, 2021Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. Chawla
-
Patent number: 11066706Abstract: The invention relates to methods and kits for diagnosing and/or treating appendicitis in a subject, comprising obtaining a biological sample from said subject; detecting RNA expression levels of at least three or more biomarkers in the biological sample and comparing the expression levels of said at least three or more biomarkers to a control sample wherein an increase or decrease in the level of expression of said at least three or more biomarkers as compared to the control sample is indicative of appendicitis.Type: GrantFiled: October 22, 2015Date of Patent: July 20, 2021Assignee: The George Washington University, A Congressionally Chartered Not-For-Profit CorporationInventors: Lakhmir S. Chawla, Timothy A. McCaffrey
-
Publication number: 20210062266Abstract: Methods and kits for diagnosing and/or treating a lower respiratory infection in a subject include obtaining a biological sample from the subject; detecting RNA expression levels of one or more biomarkers in the biological sample and comparing the expression levels of the one or more three biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of the one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.Type: ApplicationFiled: October 27, 2020Publication date: March 4, 2021Applicant: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventors: Timothy A. McCaffrey, Lakhmir S. Chawla
-
Publication number: 20200376073Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.Type: ApplicationFiled: December 23, 2019Publication date: December 3, 2020Applicant: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. CHAWLA
-
Patent number: 10851418Abstract: Methods and kits for diagnosing and/or treating a lower respiratory infection in a subject include obtaining a biological sample from the subject; detecting RNA expression levels of one or more biomarkers in the biological sample and comparing the expression levels of the one or more three biomarkers to at least one invariant control marker wherein an increase or decrease in the level of expression of the one or more biomarkers as compared to the at least one invariant control marker is indicative of a lower respiratory infection.Type: GrantFiled: January 12, 2016Date of Patent: December 1, 2020Assignee: THE GEORGE WASHINGTON UNIVERSITY A CONGRESSIONAL CHARTERED NOT-FOR-PROFIT CORPORATIONInventors: Timothy A. Mccaffrey, Lakhmir S. Chawla
-
Patent number: 10765722Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: GrantFiled: September 19, 2018Date of Patent: September 8, 2020Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. Chawla
-
Publication number: 20200271669Abstract: It is an object of the present invention to provide a combination of a functional assessment of renal function together with biomarker results in order to improve assessment of patient at risk of, or having, an acute kidney injury. A loop diuretic such as furosemide inhibits luminal active chloride transport throughout the thick ascending limb of Henle, thereby preventing sodium reabsorption and resulting in natriuresis and increased urine flow. Loop diuretic-induced increases in urine output might be a method to assess the integrity of the renal tubular function in the setting of early AM, and so a kidney's response, or lack thereof, to a diuretic challenge as a clinical assessment of tubular function can identify patients with severe tubular injury before it is clinically apparent (e.g. a rise in creatinine).Type: ApplicationFiled: March 2, 2020Publication date: August 27, 2020Applicant: ASTUTE MEDICAL, INC.Inventors: PAUL MCPHERSON, LAKHMIR S. CHAWLA
-
Patent number: 10548943Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.Type: GrantFiled: June 13, 2019Date of Patent: February 4, 2020Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. Chawla
-
Publication number: 20190374597Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.Type: ApplicationFiled: June 13, 2019Publication date: December 12, 2019Applicant: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. CHAWLA
-
Patent number: 10493124Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: GrantFiled: March 1, 2018Date of Patent: December 3, 2019Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. Chawla
-
Publication number: 20190328827Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: ApplicationFiled: April 12, 2019Publication date: October 31, 2019Inventor: Lakhmir S. CHAWLA
-
Publication number: 20190070250Abstract: The present invention relates, rider alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: ApplicationFiled: September 19, 2018Publication date: March 7, 2019Inventor: Lakhmir S. CHAWLA
-
Publication number: 20180193407Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: ApplicationFiled: March 1, 2018Publication date: July 12, 2018Applicant: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. Chawla